Literature DB >> 17054142

Interventions for treating oral leukoplakia.

G Lodi1, A Sardella, C Bez, F Demarosi, A Carrassi.   

Abstract

BACKGROUND: Oral leukoplakia is a relatively common oral lesion that in a small but significant proportion of cases changes into cancer. Since most leukoplakias are asymptomatic, the primary objective of treatment should be to prevent such malignant transformation.
OBJECTIVES: To assess effectiveness, safety and acceptability of treatments for leukoplakia. SEARCH STRATEGY: The following databases were searched for relevant trials: Cochrane Oral Health Group's Trials Register (to April 2006), CENTRAL (TheCochrane Library 2006, Issue 1), MEDLINE (from 1966 to December 2005), and EMBASE (from 1980 to December 2005). Handsearching was performed for the main oral medicine journals. References of included studies and reviews were checked. Oral medicine experts were contacted through an European mailing list (EURORALMED). SELECTION CRITERIA: Randomised controlled trials (RCTs), enrolling patients with a diagnosis of oral leukoplakia, were included. Any surgical or medical (topical and systemic) treatment was included. The primary outcome considered was malignant transformation of leukoplakia. Other outcomes considered were clinical resolution, histological modification and frequency of adverse effects. DATA COLLECTION AND ANALYSIS: Data were collected using a specific extraction form. Malignant transformation of leukoplakia, demonstrated by histopathological examination, was the main outcome considered. Secondary outcomes included clinical resolution of the lesion and variation in dysplasia severity. The validity of included studies was assessed by two review authors, on the basis of the method of allocation concealment, blindness of the study and loss of participants. Data were analysed by calculating risk ratio. When valid and relevant data were collected, a meta-analysis of the data was undertaken. MAIN
RESULTS: The possible effectiveness of surgical interventions, including laser therapy and cryotherapy, has never been studied by means of a RCT with a no treatment/placebo arm. Twenty-five eligible RCTs of non-surgical interventions were identified: 11 were excluded for different reasons, five were ongoing studies, leaving nine studies to be included in the review (501 patients). Two studies resulted at low risk of bias, six at moderate risk of bias and one at high risk of bias. Vitamin A and retinoids were tested by five RCTs, two studies investigated beta carotene or carotenoids, the other drugs tested were bleomycin (one study), mixed tea (one study) and ketorolac (one study). One study tested two treatments. Malignant transformation was recorded in just two studies: none of the treatments tested showed a benefit when compared with the placebo. Treatment with beta carotene, lycopene and vitamin A or retinoids, was associated with significant rates of clinical resolution, compared with placebo or absence of treatment. Whenever reported, a high rate of relapse was a common finding. Side effects of variable severity were often described; however, interventions were well accepted by patients, since drop-out rates were similar between treatment and control groups. AUTHORS'
CONCLUSIONS: To date there is no evidence of effective treatment in preventing malignant transformation of leukoplakia. Treatments may be effective in the resolution of lesion, however relapses and adverse effects are common.

Entities:  

Mesh:

Year:  2006        PMID: 17054142     DOI: 10.1002/14651858.CD001829.pub3

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  27 in total

1.  Marked variation in malignant transformation rates of oral leukoplakia.

Authors:  Aisling Anderson; Nurul Ishak
Journal:  Evid Based Dent       Date:  2015-12

Review 2.  Photodynamic therapy in the management of pre-malignant head and neck mucosal dysplasia and microinvasive carcinoma.

Authors:  Harry Quon; Craig E Grossman; Jarod C Finlay; Timothy C Zhu; Clarice S Clemmens; Kelly M Malloy; Theresa M Busch
Journal:  Photodiagnosis Photodyn Ther       Date:  2011-06       Impact factor: 3.631

Review 3.  Oral premalignant lesions: from a clinical perspective.

Authors:  Teruo Amagasa; Masashi Yamashiro; Narikazu Uzawa
Journal:  Int J Clin Oncol       Date:  2011-01-12       Impact factor: 3.402

Review 4.  The molecular biology of head and neck cancer.

Authors:  C René Leemans; Boudewijn J M Braakhuis; Ruud H Brakenhoff
Journal:  Nat Rev Cancer       Date:  2010-12-16       Impact factor: 60.716

Review 5.  Diagnostic tests for oral cancer and potentially malignant disorders in patients presenting with clinically evident lesions.

Authors:  Richard Macey; Tanya Walsh; Paul Brocklehurst; Alexander R Kerr; Joseph L Y Liu; Mark W Lingen; Graham R Ogden; Saman Warnakulasuriya; Crispian Scully
Journal:  Cochrane Database Syst Rev       Date:  2015-05-29

Review 6.  Molecular pathways: current role and future directions of the retinoic acid pathway in cancer prevention and treatment.

Authors:  Roisin M Connolly; Nguyen K Nguyen; Saraswati Sukumar
Journal:  Clin Cancer Res       Date:  2013-01-15       Impact factor: 12.531

Review 7.  Headway and hurdles in the clinical development of dietary phytochemicals for cancer therapy and prevention: lessons learned from vitamin A derivatives.

Authors:  Christina Y Yim; Pingping Mao; Michael J Spinella
Journal:  AAPS J       Date:  2014-01-16       Impact factor: 4.009

8.  DeltaNp63 overexpression, alone and in combination with other biomarkers, predicts the development of oral cancer in patients with leukoplakia.

Authors:  Pierre Saintigny; Adel K El-Naggar; Vali Papadimitrakopoulou; Hening Ren; You-Hong Fan; Lei Feng; J Jack Lee; Edward S Kim; Waun Ki Hong; Scott M Lippman; Li Mao
Journal:  Clin Cancer Res       Date:  2009-09-22       Impact factor: 12.531

Review 9.  Head and neck cancer.

Authors:  Athanassios Argiris; Michalis V Karamouzis; David Raben; Robert L Ferris
Journal:  Lancet       Date:  2008-05-17       Impact factor: 79.321

10.  Oral cancer screening in the Bangladeshi community of Tower Hamlets: a social model.

Authors:  H Nunn; A Lalli; F Fortune; R Croucher
Journal:  Br J Cancer       Date:  2009-12-03       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.